Xiangxue Life Sciences (XLifeSc) is a biopharmaceutical company focused on TCR-based therapies for cancer.  Our main proprietary technological platforms are composed of: (1) High Affinity T Cell Activation Core (HATac) ; (2) TCR Affinity Enhancing Specific T Cell Therapy (TAEST) .  The two platforms have been fully developed to the clinic-ready stage.  As a result, an independently-owned intellectual property portfolio has been constructed which spans across the whole spectrum of TCR-related technologies including the identification of tumor-specific antigens, antigen-specific TCRs, and the optimization of antigen-specific TCRs in terms of affinity and stability, etc.  To date, many domestic and PCT applications have been filed.

               Housing several state-of-the-art laboratories, XLifeSc is capable of offering a broad range of R&D services, including (1) large scale GMP grade lentivirus production; (2) target identification and lead optimization; (3) efficacy validation and safety testing in cell lines and animal models; (4) clinical trial development; and (5) market entry planning.  These capabilities and services can be either accessed as flexible stand-alone services on demand or as a part of integrated drug discovery programs.  To meet the needs of different partners, we welcome all types of alliance opportunities such as out-license, co-development, and co-marketing.